Multicenter prospective trial of hypofractionated radiation treatment, toceranib, and prednisone for measurable canine mast cell tumors

Journal of Veterinary Internal Medicine

Volumn 26, Issue 1, 2012, Pages 135-141

  Carlsten, K S ^a   London, C A ^b   Haney, S ^c   Burnett, R ^a   Avery, A C ^a   Thamm, D H ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c RED BANK VETERINARY HOSPITAL   (United States)

Author keywords

Palladia; Palliative

Indexed keywords

ANTINEOPLASTIC AGENT; DNA; INDOLE DERIVATIVE; PREDNISONE; PYRROLE DERIVATIVE; STEM CELL FACTOR RECEPTOR; TOCERANIB;

ANIMAL; ANIMAL DISEASE; ARTICLE; CHEMISTRY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOG; DOG DISEASE; FEMALE; GENETICS; KAPLAN MEIER METHOD; MALE; MULTICENTER STUDY; PATHOLOGY; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; RADIOGRAPHY; SARCOMA; SKIN TUMOR;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DNA, NEOPLASM; DOG DISEASES; DOGS; FEMALE; INDOLES; KAPLAN-MEIER ESTIMATE; MALE; MAST-CELL SARCOMA; POLYMERASE CHAIN REACTION; PREDNISONE; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS C-KIT; PYRROLES; SKIN NEOPLASMS;

ANIMALIA; CANIS FAMILIARIS;

EID: 84855734654     PISSN: 08916640     EISSN: 19391676     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2011.00851.x     Document Type: Article

References (27)

1. Bostock DE. Neoplasms of the skin and subcutaneous tissues in dogs and cats. Br Vet J 1986;142:1-19.
2. Brodey RS. Canine and feline neoplasia. Adv Vet Sci Comp Med 1970;14:309-354.
3. Turrel JM, Kitchell BE, Miller LM, et al. Prognostic factors for radiation treatment of mast cell tumor in 85 dogs. J Am Vet Med Assoc 1988;193:936-940.
4. Gillette EL. Indications and selection of patients for radiation therapy. Vet Clin North Am 1974;4:889-896.
5. Gillette EL. Radiation therapy of canine and feline tumors. J Am Anim Hosp Assoc 1976;12:359-362.
6. Gillette EL. Veterinary radiotherapy. J Am Vet Med Assoc 1976;157:1707-1712.
7. McClelland RB. The treatment of mastocytomas in dogs. Cornell Vet 1964;54:517-519.
8. Allan GS, Gillette EL. Response of canine mast cell tumors to radiation. J Natl Cancer Inst 1979;63:691-694.
9. Dobson J, Cohen S, Gould S. Treatment of canine mast cell tumours with prednisolone and radiotherapy. Vet Comp Oncol 2004;2:132-141.
10. London CA, Hannah AL, Zadovoskaya R, et al. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clin Cancer Res 2003;9:2755-2768.
11. London CA, Malpas PB, Wood-Follis SL, et al. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin Cancer Res 2009;15:3856-3865.
12. Cuneo KC, Geng L, Fu A, et al. SU11248 (sunitinib) sensitizes pancreatic cancer to the cytotoxic effects of ionizing radiation. Int J Radiat Oncol Biol Phys 2008;71:873-879.
13. Yoon SS, Stangenberg L, Lee YJ, et al. Efficacy of sunitinib and radiotherapy in genetically engineered mouse model of soft-tissue sarcoma. Int J Radiat Oncol Biol Phys 2009;74:1207-1216.
14. Zwolak P, Jasinski P, Terai K, et al. Addition of receptor tyrosine kinase inhibitor to radiation increases tumour control in an orthotopic murine model of breast cancer metastasis in bone. Eur J Cancer 2008;44:2506-2517.
15. Kao J, Packer S, Vu HL, et al. Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: Acute toxicity and preliminary response. Cancer 2009;115:3571-3580.
16. Schueneman AJ, Himmelfarb E, Geng L, et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res 2003;63:4009-4016.
17. Bo LD, Dennis E. Tumor angiogenesis as a strategy for radiosensitization. Cancer Ther 2003;1:8.
18. Jalal Hosseinimehr S, Inanami O, Hamasu T, et al. Activation of c-kit by stem cell factor induces radioresistance to apoptosis through ERK-dependent expression of survivin in HL60 cells. J Radiat Res (Tokyo) 2004;45:557-561.
19. Yancey MF, Merritt DA, Lesman SP, et al. Pharmacokinetic properties of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors. J Vet Pharmacol Ther 2010;33:162-171.
20. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247.
21. Vail DM. Veterinary co-operative oncology group. Vet Comp Oncol 2004;2:194.
22. Carsten RE, Hellyer PW, Bachand AM, et al. Correlations between acute radiation scores and pain scores in canine radiation patients with cancer of the forelimb. Vet Anaesth Analg 2008;35:355-362.
23. McCaw DL, Miller MA, Ogilvie GK, et al. Response of canine mast cell tumors to treatment with oral prednisone. J Vet Intern Med 1994;8:406-408.
24. Webster JD, Yuzbasiyan-Gurkan V, Kaneene JB, et al. The role of c-KIT in tumorigenesis: Evaluation in canine cutaneous mast cell tumors. Neoplasia 2006;8:104-111.
25. Downing S, Chien MB, Kass PH, et al. Prevalence and importance of internal tandem duplications in exons 11 and 12 of c-kit in mast cell tumors of dogs. Am J Vet Res 2002;63:1718-1723.
26. Webster JD, Yuzbasiyan-Gurkan V, Miller RA, et al. Cellular proliferation in canine cutaneous mast cell tumors: Associations with c-KIT and its role in prognostication. Vet Pathol 2007;44:298-308.
27. London CA. Tyrosine kinase inhibitors in veterinary medicine. Top Companion Anim Med 2009;24:106-112.